Survival benefit from abemaciclib in non–small cell lung cancer by Kirsten rat sarcoma–mutation gene expression subtype: retrospective analysis from the JUNIPER Trial
Patients with KL expression subtype tumors may derive better OS and PFS from abemaciclib versus erlotinib in <i>KRAS</i>-mutated non-small cell lung cancer. These results should be further validated in an independent dataset.
Authors
- Marı́a José Lallena (ORCID: https://orcid.org/0000-0002-6617-798X)
- Philip J. Ebert (ORCID: https://orcid.org/0000-0002-8945-2948)
- Elisabet Zapatero‐Solana
- S. Velasco (ORCID: https://orcid.org/0000-0001-6835-2967)
- Shawn T. Estrem
- Amit Aggarwal
- Gloria Martı́nez del Hoyo (ORCID: https://orcid.org/0000-0003-2588-2575)
- Sandra Peregrina
- Jiangang Liu (ORCID: https://orcid.org/0000-0002-2800-077X)
- Hong Wang (ORCID: https://orcid.org/0000-0003-0477-2908)
- Xueqian Gong
- Anwar M. Hossain
- María Jesús Ortiz-Ruiz
Institutions
- Eli Lilly (United States) (US)
- Eli Lilly (Spain) (ES)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-03-31
- DOI
- https://doi.org/10.3389/fonc.2025.1461530
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company